In:
Cancer, Wiley, Vol. 126, No. 17 ( 2020-09), p. 4002-4012
Kurzfassung:
To the authors' knowledge, the current study is the first biomarker‐driven umbrella study in patients with recurrent and refractory small cell lung cancer (SCLC) using adavosertib, vistusertib, and AZD2811NP. Although the overall outcome of this study fails to satisfy the primary endpoint, the results provide the rationale to focus on the exploration of combination approaches for the treatment of patients with recurrent and refractory SCLC.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v126.17
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2020
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1